Stay updated with breaking news from Nasdaq Amph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com lowered shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) from a buy rating to a hold rating in a research report released on Tuesday morning. Separately, Bank of America started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 17th. They issued a neutral rating and a $63.00 price objective on the […]
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Volatility and Risk Amphastar Pharmaceuticals has a […]
Guidance Capital Inc. purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 6,885 shares of the company’s stock, valued at approximately $377,000. Other hedge funds and other institutional investors […]
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) EVP Rong Zhou sold 3,514 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $59.58, for a total transaction of $209,364.12. Following the completion of the sale, the executive vice president now owns 112,420 shares […]
Renaissance Technologies LLC cut its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 0.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 492,583 shares of the company’s stock after selling 4,217 shares during the period. Renaissance Technologies LLC […]